α‐synuclein RT‐QuIC in cerebrospinal fluid of LRRK 2‐linked Parkinson's disease
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Leucine‐rich kinase 2 (LRRK 2)‐linked Parkinson's disease (PD) is clinically indistinguishable from idiopathic PD (IPD). A pleiotropic neuropathology has been recognized but the majority of studies in LRRK 2 p.G2019S patients reveal Lewy‐type synucleinopathy as its principal histological substrate. To date no in vivo biomarkers of synucleinopathy have been found in LRRK 2 mutation carriers. Objectives: We used real‐time quaking‐induced conversion (RT‐Qu IC) technique to assess the presence of alpha‐synuclein (a‐syn) aggregates in cerebrospinal fluid (CSF) of LRRK 2 p.G2019S carriers. Methods: CSF samples of 51 subjects were analyzed: 15 LRRK 2 p.G2019S PD, 10 IPD, 16 LRRK 2 p.G2019S nonmanifesting carriers (NMC) and 10 healthy controls. The presence of parkinsonism and prodromal symptoms was assessed in all study subjects. Results: Forty percent (n = 6) L RRK 2‐PD, and 18.8% (n = 3) LRRK2‐NMC had a positive a‐syn RT‐Qu IC response. RT‐Qu IC detected IPD with 90% sensitivity and 80% specificity. No clinical differences were detected between LRRK 2‐PD patients with positive and negative RT‐Qu IC. A positive RT‐Qu IC result in LRRK 2‐NMC occurred in a higher proportion of subjects meeting the Movement Disorder Society research criteria for prodromal PD. Interpretation: RT‐Qu IC detects a‐syn aggregation in CSF in a significant number of patients with LRRK 2‐PD, but less frequently than in IPD. A small percentage of LRRK 2‐NMC tested also positive. If appropriately validated in long‐term studies with large number of mutation carriers, and hopefully, postmortem or in vivo confirmation of histopathology, RT‐Qu IC could contribute to the selection of candidates to receive disease modifying drugs, in particular treatments targeting a‐syn deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goetz, C. G., Tilley, B. C., Shaftman, S. R., Stebbins, G. T., Fahn, S., Martinez‐Martin, P., Poewe, W., Sampaio, C., Stern, M. B., Dodel, R., et al. (2008) · Movement Disorders · doi:10.1002/mds.22340 · Cited by 7,536
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein
Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., & Lee, S.-J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903691106 · Cited by 1,485 · cited 1×
“This technique, previously used as a diagnostic tool in diseases caused by prion proteins, is based on the capacity of misfolded a-syn to induce the aggregation of monomeric species of a-syn.(17,18) Fairfoul and colleagues demonstrated in CSF of pathologically confirmed patients with Lewy body disease a positivity of…”
MethodAlpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608
Self-citationMollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., Ng, J., Schulz-Schaeffer, W., Kretzschmar, H. A., McLean, P. J., et al. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2008.06.004 · Cited by 382
Use of the Beck Depression Inventory-II with depressed geriatric inpatients
Steer, R. A., Rissmiller, D. J., & Beck, A. T. (2000) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(99)00068-6 · Cited by 238
Lewy Body Pathology in Normal Elderly Subjects
Markesbery, W. R., Jicha, G. A., Liu, H., & Schmitt, F. A. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181ac10a7 · Cited by 210
In vivo gastric detection of α-synuclein inclusions in Parkinson's disease
Sánchez‐Ferro, Á., Rábano, A., Catalán, M. J., Rodríguez‐Valcárcel, F. C., Díez, S. F., Herreros‐Rodríguez, J., García‐Cobos, E., Álvarez‐Santullano, M. M., López‐Manzanares, L., Mosqueira, A. J., et al. (2015) · Movement Disorders · doi:10.1002/mds.25988 · Cited by 123
Cited by
Challenges in the diagnosis of Parkinson's disease
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00030-2 · Cited by 1,874
Self-citationSiderowf, A., Concha-Marambio, L., Lafontant, D.-E., Farris, C. M., Ma, Y., Urenia, P. A., Nguyen, H., Alcalay, R. N., Chahine, L. M., Foroud, T., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00109-6 · Cited by 719
Rossi, M., Candelise, N., Baiardi, S., Capellari, S., Giannini, G., Orrù, C. D., Antelmi, E., Mammana, A., Hughson, A. G., Calandra-Buonaura, G., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02160-8 · Cited by 451
LRRK2 in Parkinson disease: challenges of clinical trials
Tolosa, E., Vila, M., Klein, C., & Rascol, O. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0301-2 · Cited by 438
Self-citationNeuropathology and molecular diagnosis of Synucleinopathies
Koga, S., Sekiya, H., Kondru, N., Ross, O. A., & Dickson, D. W. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00501-z · Cited by 347
Iranzo, A., Fairfoul, G., Ayudhaya, A. C. N., Serradell, M., Gelpi, E., Vilaseca, I., Sanchez-Valle, R., Gaig, C., Santamaria, J., Tolosa, E., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30449-x · Cited by 327
Self-citationSkin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease
Wang, Z., Becker, K., Donadio, V., Siedlak, S., Yuan, J., Rezaee, M., Incensi, A., Kuzkina, A., Orrú, C. D., Tatsuoka, C., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3311 · Cited by 253
Perspective on the current state of the LRRK2 field
Taymans, J.-M., Fell, M., Greenamyre, T., Hirst, W. D., Mamais, A., Padmanabhan, S., Peter, I., Rideout, H., & Thaler, A. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00544-7 · Cited by 153
Rivero-Ríos, P., Romo-Lozano, M., Fasiczka, R., Naaldijk, Y., & Hilfiker, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00556 · Cited by 31
Metadata
- Authors
- Garrido, A., Fairfoul, G., Tolosa, E. S., Martí, M. J., Green, A., & the Barcelona LRRK2 Study Group
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2019-05-09
- Volume
- 6
- Issue
- 6
- Pages
- 1024-1032
- ISSN
- 2328-9503 (ISSN-L)
- OpenAlex
- W2944521680
- Cited by
- 109
- References
- 8
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.